Last reviewed · How we verify

Apatinib Combined With Docetaxel — Competitive Intelligence Brief

Apatinib Combined With Docetaxel (Apatinib Combined With Docetaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tyrosine kinase inhibitor. Area: Oncology.

phase 2 tyrosine kinase inhibitor VEGFR2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Apatinib Combined With Docetaxel (Apatinib Combined With Docetaxel) — Jiangsu ShengDiYa Medicine Co., Ltd.. Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Apatinib Combined With Docetaxel TARGET Apatinib Combined With Docetaxel Jiangsu ShengDiYa Medicine Co., Ltd. phase 2 tyrosine kinase inhibitor VEGFR2
REGORAFENIB REGORAFENIB marketed RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R 2012-01-01
Sutent Sunitinib Malate Pfizer marketed Small molecule kinase inhibitor Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET 2006-01-01
Anlotinib(blank) Anlotinib(blank) Chia Tai Tianqing Pharmaceutical Group Co., Ltd. phase 3 Multi-targeted tyrosine kinase inhibitor VEGFR2, FGFR1, PDGFR-β, c-Kit, Ret
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan Jiangsu HengRui Medicine Co., Ltd. phase 3 Monoclonal antibody (ramucirumab) + chemotherapy combination VEGF receptor 2 (VEGFR2); tubulin (taxanes) / topoisomerase I (irinotecan)
Camrelizumab and Apatinib Camrelizumab and Apatinib Chinese Academy of Medical Sciences phase 3 PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination PD-1 (camrelizumab); VEGFR2 (apatinib)
Fluzoparib; Apatinib Fluzoparib; Apatinib Jiangsu HengRui Medicine Co., Ltd. phase 3 PARP inhibitor + tyrosine kinase inhibitor (combination therapy) PARP1/PARP2; VEGFR2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tyrosine kinase inhibitor class)

  1. Centre Leon Berard · 2 drugs in this class
  2. Akeso · 1 drug in this class
  3. Astex Pharmaceuticals, Inc. · 1 drug in this class
  4. Chengdu Zenitar Biomedical Technology Co., Ltd · 1 drug in this class
  5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  6. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 drug in this class
  7. Nanjing Leads Biolabs Co.,Ltd · 1 drug in this class
  8. Ocular Therapeutix, Inc. · 1 drug in this class
  9. Peking University Cancer Hospital & Institute · 1 drug in this class
  10. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Apatinib Combined With Docetaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/apatinib-combined-with-docetaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: